The herpes simplex virus (HSV) is a viral infection that causes genital and oral herpes. It is a very contagious virus that causes infections. There are two types of HSV, such as HSV-1 and HSV-2. There is no cure for genital herpes, however, daily use of antiviral medicines can prevent or shorten outbreaks, and reduce the chance of spreading it to others. Thus, there is an increasing demand for safe and effective herpes simplex virus treatment worldwide.

Market Dynamics:

Increase in prevalence of infections of the herpes simplex virus, rise in number of clinical trials, increase in demand for safe and effective HSV treatment, and increase in awareness among people about herpes simplex virus are major factors expected to augment the growth of the global herpes simplex virus treatment market over the forecast period.

For instance, in October 2021, United BioPharma, Shanghai Public Health Clinical Centre, and Department of Microbiology (Cheng Kung University) and Immunology teamed up to investigate the efficacy of UB-621, a best-in-class long-acting medicine for genital herpes caused by simplex viruses 1 and 2 (HSV 1 and 2). Moreover, the World Health Organization (WHO) and partners support research to develop new strategies for prevention and control of HSV infections.

Key features of the study:

• This report provides in-depth analysis of the global herpes simplex virus treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2023–2030), considering 2022 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global herpes simplex virus treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Fresenius SE & Co. KgaA, Glenmark Pharmaceuticals, Carlsbad Tech, GlaxoSmithKline PLC, Zydus Cadila, Epi Health LLC, Viatris Inc., Apotex Inc., Teva Pharmaceuticals Industries Ltd., and Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.), among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global herpes simplex virus treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herpes simplex virus treatment market.

Detailed Segmentation:

• Global Herpes Simplex Virus Treatment Market By Drug Type:
  • Acyclovir
  • Valacyclovir
  • Famciclovir
  • Other Drugs
• Global Herpes Simplex Virus Treatment Market By Route of Administration:
  • Oral
  • Injection
  • Topical
• Global Herpes Simplex Virus Treatment Market By Geography:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Company Profiles:
  • Fresenius SE & Co. KgaA
  • Glenmark Pharmaceuticals
  • Carlsbad Tech
  • GlaxoSmithKline PLC
  • Zydus Cadila
  • Epi Health LLC
  • Viatris Inc.
  • Apotex Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Emcure Pharmaceuticals Ltd (Avet Pharmaceuticals Inc.)